OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) 13D and 13G filings for Heron Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
2023-02-13 07:29 am Sale |
2022-12-30 | 13G | Heron Therapeutics, Inc. HRTX |
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 0 0.000% |
-8,275,000![]() (Position Closed) |
Filing |
2022-02-14 11:17 am Purchase |
2021-12-31 | 13G | Heron Therapeutics, Inc. HRTX |
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 8,275,000 8.120% |
8,275,000![]() (New Position) |
Filing |